Core Viewpoint - CloudBreak Therapeutics has successfully listed on the Hong Kong Stock Exchange, marking a significant milestone as the first international ophthalmic innovation drug company to go public in Hong Kong, with a market capitalization of HKD 84.73 billion and net fundraising of approximately HKD 5.22 billion [2][4] Company Overview - Founded in 2015 in Irvine, California, CloudBreak Therapeutics is a clinical ophthalmic biotechnology company focused on innovative and differentiated therapies, with a mission to ensure that no one is hindered by poor eye health [4] - The company has developed a broad and innovative pipeline, including eight drug candidates targeting major diseases of the anterior and posterior segments of the eye, with four in clinical stages and four in preclinical stages [4] Product Pipeline - The core product CBT-001 is a pioneering drug for the treatment of pterygium, currently undergoing global Phase III clinical trials across multiple countries, showing significant efficacy and good tolerability [6][10] - Other products in the pipeline include CBT-004 for treating vascularized pterygium, CBT-006 for dry eye syndrome, and CBT-009 for myopia in adolescents, all demonstrating promising clinical results [12][13] Market Opportunity - The global prevalence of pterygium is 10.2%, with rural areas in China reaching as high as 33%, indicating a significant unmet medical need in this area [7][10] - The global ophthalmic drug market is projected to reach USD 73.9 billion by 2030, highlighting the growth potential for innovative therapies in this sector [16] Investment and Support - Since 2018, CloudBreak Therapeutics has raised a total of HKD 11.3 billion, receiving support from various institutions, including Yi Feng Capital, which participated in its C-round financing in 2022 [14][15] - The successful IPO is seen as a validation of the company's core value and clear development path, with expectations for its innovative products to capture significant market share in the global ophthalmic drug market [15][18]
港股国际化眼科创新药第一股！拨康视云成功登陆港交所